Cell MedX Corp. Announces a Non-Brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - April 17, 2020) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company has arranged a non-brokered private placement offering (the "Offering") set at a price of $0.25 per Unit for up to 1,000,000 Units for total gross proceeds of $250,000. Each Unit sold under...
2020-04-17 8:00 AM EDT
Cell MedX Corp. Receives Quality Management System ISO 13485:2016 Certificate for the eBalance(R) Device
Carson City, Nevada--(Newsfile Corp. - April 7, 2020) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received a Quality Management System - ISO 13485:2016 certification for the Company's eBalance® device (the "Device").At the end of February 2020 BSI Group Canada...
2020-04-07 8:00 AM EDT
Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalance(R) Device
Carson City, Nevada--(Newsfile Corp. - January 30, 2020) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has repurchased the worldwide exclusive direct rights for distribution of its eBalance® devices.Cell MedX identified two distribution market channels for sales of the...
2020-01-30 8:00 AM EST
Cell MedX Corp. Engages Dr. Peter Eppinga as Lead Investigator in the eBalance(R) R&D Experience Study
Carson City, Nevada--(Newsfile Corp. - December 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has recruited Dr. Peter Eppinga, a family practice physician (MD, CCFP) licensed in the province of British Columbia, Canada, as the lead investigator in the eBalance®...
2019-12-12 8:00 AM EST
Cell MedX Corp. Receives eBalance Trademark
Carson City, Nevada--(Newsfile Corp. - October 17, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the European Union has approved the Company's eBalance trademark application, and issued certificate of registration number 017997155 registering the trademark eBalance in the name of the...
2019-10-17 8:00 AM EDT
Cell MedX Corp. Provides Corporate Update
Carson City, Nevada--(Newsfile Corp. - September 12, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with a corporate update. Certifications In Fiscal year 2019 the Company received a Certificate of Conformity, from LabTest Certification Inc., for the ebalance Pro device (the...
2019-09-12 8:00 AM EDT
Cell MedX Corp. Issues Clarifying Release Regarding the Bull Report Article
Carson City, Nevada--(Newsfile Corp. - September 10, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focused on the discovery, development and commercialization of therapeutic and nontherapeutic products that promote general wellness, is issuing this news release to clarify that the article dated July 24, 2019 appearing in the TheBullReport.com was prepared on behalf of the Company.As previously announced, the Company has engaged the services of Think...
2019-09-10 5:34 PM EDT
CellMedX Corp. Receives Approval to Commence Family Practice (BC) Observational Study
Carson City, Nevada--(Newsfile Corp. - August 19, 2019) - Cell MedX Corp. (OTCQB: CMXC) (MUN: 9CX) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that the Company has received approval from the Board of Directors to commence a Family Practice (BC) - Observational Study of its ebalance device (the "Observational Trial", or the...
2019-08-19 8:00 AM EDT
Cell MedX Corp. (CMXC) Closes the First Tranche of its Non-Brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - June 28, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on June 24, 2019, the Company closed the first tranche of its non-brokered private placement offering (the "Offering") at a price of $0.12 per unit (the "Unit"), by issuing 3,950,000 Units for...
2019-06-28 11:12 AM EDT
Cell MedX Corp. Engages Think Ink Marketing
Carson City, Nevada--(Newsfile Corp. - June 21, 2019) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that it has retained Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to develop an investor outreach program. The Company agreed to pay Think Ink $25,000 for the first month of...
2019-06-21 8:55 PM EDT
Cell MedX Corp. Arranges a Non-brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - May 30, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arranged a non-brokered private placement offering (the "Offering") set at a price of $0.12 per Unit for up to 6,250,000 Units for total gross proceeds of $750,000. Each Unit sold under the Offering will consist of one...
2019-05-30 2:22 PM EDT
Cell MedX Signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc.
Carson City, Nevada--(Newsfile Corp. - March 27, 2019) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on March 21, 2019, the Company entered into a definitive agreement for exclusive worldwide distribution rights of the ebalance device for home-use ("the "Agreement") with Live Current...
2019-03-27 8:00 AM EDT
Cell MedX Corp. Provides an Update on Progress Toward US Premarket Clearance and Clarifies its eBalance Certification
Carson City, Nevada--(Newsfile Corp. - February 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. The eBalance device is not yet available for sale in the US.The Company has been...
2019-02-12 8:00 AM EST
Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants
Carson City, Nevada--(Newsfile Corp. - December 31, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the "Lender"), the Company's major shareholder (the "Agreement"), for an unsecured line of...
2018-12-31 3:00 PM EST
Cell MedX Corp. Manufactures eBalance Devices in Canada
Carson City, Nevada--(Newsfile Corp. - December 12, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices.Upon receiving its Certificate of Conformity, qualifying the eBalance devices as...
2018-12-12 8:00 AM EST
Cell MedX Corp. Receives Safety and Electrical Certifications for the eBalance Pro Device
Carson City, Nevada--(Newsfile Corp. - December 4, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company's eBalance Pro device (the "Device"). The Company has received a Certificate of...
2018-12-04 8:00 AM EST
Cell MedX Corp Signs Letter of Intent for Worldwide Distribution Rights and Enters into Royalty Agreement Contracts
Carson City, Nevada--(Newsfile Corp. - September 14, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on September 10, 2018, the Company entered into a non-binding letter of intent (the "LOI") with Live Current Media, Inc. ("LIVC"), an arms-length party, for worldwide distribution...
2018-09-14 12:12 PM EDT
Dr. Terrance Owen Resigns as CEO of Cell MedX Corp
Carson City, Nevada--(Newsfile Corp. - May 7, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, effective April 30, 2018, Dr. Terrance Owen resigned from his management and directorship positions with Cell MedX. The resignation of Dr. Owen was not due to any...
2018-05-07 3:50 PM EDT
Cell MedX Corp. Appoints Dr. George Adams as Director
Carson City, Nevada--(Newsfile Corp. - March 26, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), an early-stage biotech company focusing on the discovery, development and commercialization of products that promote general wellness, is pleased to announce that it has appointed Dr. George Adams to the Board of Directors. "Cell MedX has just completed a clinical trial where it has demonstrated a significant lowering of blood pressure in patients with known...
2018-03-26 8:00 AM EDT
Cell MedX Corp. Arranges a Non-Brokered Private Placement Financing
Carson City, Nevada--(Newsfile Corp. - March 19, 2018) - Cell MedX Corp. (OTCQB: CMXC) (9CX: MUN), ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes has arranged a non-brokered private placement offering (the "Offering") set at a price of US$0.10 per Unit for 10,000,000 Units for total gross proceeds of $1,000,000. Each Unit sold under the Offering consists of one common share...
2018-03-19 8:00 AM EDT